11/16/2023
Quick Summary - Weight Loss Drugs Don't How Money Works Seminar. Don't bother reading this if you or a loved one isn't struggling with obesity, just go have a nice day. However, If you or a loved one is considering this approach, please read on for for details...
Many weight-loss medications on the market have serious potential side effects.
-Qsymia, which contains phentermine (the phen in fen-phen), can cause seizures if stopped abruptly. Although it was rejected in Europe for safety concerns about its long-term effects on the heart and blood vessels, at the time of this writing, it was still available in the United States.
-Belviq is another weight-loss drug allowed in the United States but not in Europe due to concerns about cancers, heart valve problems, and psychiatric disorders.
-Saxenda requires daily injections, costs nearly $1,300 for a 30-day supply, and carries a black box warning for thyroid cancer risk.
-Contrave also carries a black box warning—about possible increased thoughts of su***de.
-Alli causes fat malabsorption, which may result in such side effects as “f***l urgency, oily stool, flatus with discharge, and f***l incontinence.” Although company-sponsored studies claimed every adverse event related to Alli was recorded, a Freedom of Information Act exposé found that one trial apparently failed to mention 1,318 of them.
An analysis of more than a hundred clinical trials lasting up to 47 weeks of anti-obesity medications found that drug-induced weight loss never exceeded more than nine pounds.
Since the underlying cause (a fattening diet) isn’t treated, weight tends to return upon stopping the medication.
Most users of weight-loss medications stop taking them because they’re so disagreeable.
Researchers have found that many physicians tend to overestimate the amount of weight that can be lost with these drugs or just don’t know.
The principal author of clinical practice guidelines that go out of their way to advocate prescribing medications for obesity is significantly linked to six pharmaceutical companies that work on obesity drugs. In contrast, independent expert panels (e.g., Canadian Task Force on Preventive Health Care) explicitly recommend against their use, due to their poor track record of safety and efficacy.